Clinical trials: Paranoid Delusions
Schizophrenia, Schizotypal Disorder
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- PROBAS (NCT04874974)
- Testing
- Metacognitive and Defusion Training
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
The primary objective for this study is to evaluate whether Rituximab as compared to placebo is a clinically effective treatment for a subgroup of patients suffering from psychosis and/or obsessive-compulsive disorder (OCD) or…
- Conditions
- Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia, Delusional Disorder
- Trial name
- Ra-P-OCD (NCT04323566)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Uppsala University Hospital
Schizophrenia, Schizo Affective Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05756855
- Testing
- adapted behavioral intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Schizophrenia, Schizophreniform Disorders
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
The goal of this clinical trial is to compare the efficacy of combined REHACOP + MCT alone in persons with nonaffective psychotic disorder in terms of recovery.
- Conditions
- Schizophrenia, Schizophreniform Disorders, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- CR+MCTp (NCT06423651)
- Testing
- Cognitive Remediation (REHACOP), Metacognitive Training (MCT)
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- Universitat Autonoma de Barcelona
Chronic Mental Illness, Chronic Physical Illness
Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project
The Wellness Incentives and Navigation (WIN) project is designed to help improve health self-management and reduce the incidence and consequences of chronic disease among non-elderly adult Medicaid Supplemental Security Income…
- Trial name
- WIN (NCT02440906)
- Testing
- Patient-Directed Wellness Account, Health Navigator
- Where
- United States
- Volunteers
- 1,663 people
- Sponsor
- University of Florida
Schizophrenia, Hallucinations
Evaluation of Internet-based Cognitive Behavioral Self-help Treatments for People With Psychosis
Schizophrenia is a severe mental disorder which is accompanied by an enormous individual and societal burden. Despite established efficacy of cognitive behavioral therapy for psychosis (CBTp), its dissemination into routine…
- Conditions
- Schizophrenia, Hallucinations, Persecutory Delusion
- Trial name
- EviBaS (NCT02974400)
- Testing
- Internet-based, CBT-oriented, guided self-help
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 101 people
- Sponsor
- University of Bern
Schizophrenia, Schizoaffective Disorder
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
Since side effects of antipsychotics, dopamine D2 receptor blockers, frequently occur in older patients with schizophrenia and the risk is dose dependent, clinical guidelines universally advocate the use of lower doses.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT00716755
- Testing
- Risperidone/Olanzapine and PET scans
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Enhancing Veteran-Clinical Collaboration in VA PRRCs
Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Bipolar Disorder
- Trial name
- EVCC VPRRC (NCT06898879)
- Testing
- Collaborative Decision Skills Training, Leveling Up
- Where
- 3 sites in United States
- Volunteers
- 119 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Psychosis
Immune Mechanisms of Antipsychotic Treatment Response
The aim of this study is to investigate the role of the immune system in psychotic symptoms and their response to treatment. The investigators will collect blood and cerebrospinal fluid samples from participants with psychosis…
- Trial name
- IMAT (NCT06687694)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- King's College London
Paranoia, Persecutory Delusion
Recovery From Paranoia: a Qualitative Exploration
Paranoia, the experience of undue or excessive mistrust, exists on a continuum which includes suspicious thoughts, ideas of reference, and persecutory delusions.
- Trial name
- NCT04824781
- Testing
- Qualitative interview
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- University of Oxford
Schizophrenia
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make…
- Trial name
- NCT00742079
- Testing
- D-cycloserine, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT01981759
- Testing
- D-Cycloserine, Cognitive Behavioral Therapy
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- NYU Langone Health
Schizophrenia, Schizoaffective Disorder
Shared Decision Making for Antipsychotic Medications
This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05416658
- Testing
- The Antipsychotic Medication Decision Aid (APM-DA)
- Volunteers
- 120 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Mania
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and…
- Conditions
- Schizophrenia, Mania, Delusional Disorder, Acute Exacerbation of Psychosis
- Trial name
- NCT00644800
- Testing
- Ziprasidone
- Where
- 8 sites in Brazil
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
Adapting and Examining Collaborative Decision Skills Training Among Veterans With Serious Mental Illness
Recovery-oriented care is an imperative for the VA, particularly in mental health programming for Veterans with serious mental illness (SMI).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Major Depressive Disorder With Psychotic Features
- Trial name
- CDST (NCT04324944)
- Testing
- Collaborative Decision Skills Training, Leveling Up
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizotypal and Delusional Disorders, Bipolar Affective Disorder
Improving Work Outcome for People With Severe Mental Illness
The purpose of this study is to investigate the efficacy of IPS in Denmark and compare effects of 1. Individual Placement and Support (IPS) vs. 2. IPS + cognitive remediation and work-related social skills training vs. 3.
- Conditions
- Schizophrenia, Schizotypal and Delusional Disorders, Bipolar Affective Disorder, Recurrent Depressive Disorder
- Trial name
- NCT01722344
- Testing
- Individual Placement and support (IPS), IPS plus
- Where
- Denmark
- Volunteers
- 717 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Schizophrenia, Schizoaffective Disorder
Anticholinergic Burden in Schizophrenia
Anticholinergic antiparkinsonian agents often cause side-effects including cognitive impairment, dry mouth, and constipation while they diminish antipsychotic-induced parkinsonian symptoms.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT00715377
- Testing
- Benztropine
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia Disorders, Paranoid Delusions
Asylumseekers Experiencing Paranoid Delusions: A Virtual Reality Study
Rationale: Ethnic minorities and asylumseekers have a two- to three-times increased risk of psychosis compared to people from their host country. Among patients experiencing psychosis, paranoid delusions are a common symptom.
- Trial name
- COA-VR (NCT06692530)
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen